Safety of linezolid in patients with decreased renal function and trough monitoring: a systematic review and meta-analysis.

ABSTRACT:

Background

Linezolid causes hematological toxicity, mostly thrombocytopenia, which leads to treatment discontinuation and failure. Recent studies revealed that during linezolid therapy, the incidence of treatment-related hematological toxicity is significantly higher in patients with decreased renal function (DRF) than in those with normal renal function. Linezolid monitoring is necessary due to the high frequency of hematological toxicity in patients with DRF and the relationship between blood concentration and safety. We performed a systematic review and meta-analysis to evaluate the safety correlation between DRF and trough monitoring.

Methods

Articles published before June 24, 2022, on MEDLINE, Web of Sciences, Cochrane Register of Controlled Trials, and ClinicalTrials.g

SUBMITTER: Liu X 

PROVIDER: S-EPMC9714190 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature